UK markets close in 16 minutes

DBV Technologies S.A. (0QAJ.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
1.3270-0.0030 (-0.23%)
As of 03:56PM GMT. Market open.
Full screen
Previous close1.3300
Open1.3720
Bid1.2850 x 0
Ask1.3500 x 0
Day's range1.2910 - 1.3720
52-week range1.0990 - 4.1960
Volume5,387
Avg. volume3,463
Market cap150.516M
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

    Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K wi

  • Globe Newswire

    DBV Technologies Reports Full Year 2023 Financial Results and Business Update

    Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Strengthened executive leadership team in preparation for BLA submissionReported cash and cash equivalents of $141 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa

  • Globe Newswire

    DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

    Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m. ET to review full year 2023 financial results and provide a business update. Intereste